Lv4
476 积分 2025-03-05 加入
First-line immunotherapy with or without chemotherapy versus BRAF plus MEK inhibitors in BRAFV600E-mutated metastatic non-small-cell lung cancer (FRONT-BRAF): a multicentre, retrospective cohort study
4个月前
已完结
Bortezomib plus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 Trial
4个月前
已关闭
Combined immunophenotyping of tumor-infiltrating lymphocytes as a prognostic factor in resected patients with non-small cell lung cancer
5个月前
已关闭
EP1.03-23 Update of the Analysis of the Status of Lymphocyte Infiltration in Patients with NSCLC
5个月前
已完结
Prognostic and predictive role of FOXP3 positive tumor infiltrating lymphocytes (TILs) in curatively resected non small cell lung cancer other than stage IA
5个月前
已完结
Evolving roles of MET as a therapeutic target in NSCLC and beyond
5个月前
已完结
Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis
5个月前
已完结
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
5个月前
已完结
The prognostic value of tumor-infiltrating lymphocytes in non-small cell lung cancer patients who received neoadjuvant chemotherapy followed by surgery
5个月前
已完结
皖公网安备34019202002308
